GoodRx announced a partnership with Eli Lilly that will allow eligible self‑pay patients to obtain the newly FDA‑approved oral GLP‑1 medication Foundayo (orforglipron) and the Zepbound KwikPen. Foundayo, approved on April 1, 2026, will be available through GoodRx at a starting price of $149 per month, while the Zepbound KwikPen will start at $299 per month.
GoodRx’s most recent quarterly results showed revenue of $194.8 million, beating the $193.27 million consensus estimate, and an adjusted earnings per share of $0.09, a beat on the $0.08 estimate. The company’s gross profit margin stood at 92.77 percent and its adjusted EBITDA margin at 33.4 percent. However, prescription‑transactions revenue fell 6 percent and monthly active consumers declined 14 percent in 2025, while the Pharma Direct segment grew 41 percent year‑over‑year to $151.4 million from $107.2 million.
The revenue beat was driven by strong demand in GoodRx’s core segments, offsetting the decline in prescription‑transactions revenue. The company’s high gross‑profit margin and disciplined cost structure helped it maintain profitability even as overall transaction volume contracted. The EPS beat can be attributed to the same cost discipline, coupled with the high margin profile of the new GLP‑1 partnership and the continued growth of the Pharma Direct business.
GoodRx’s guidance for 2026 Adjusted EBITDA was set at a midpoint of $230 million, below the consensus estimate of $283 million. The miss reflects management’s caution amid declining prescription‑transaction revenue and a shrinking base of active consumers, while the company emphasizes preserving margin strength and operating with rigor as it expands its Pharma Direct offering.
Wendy Barnes, President and CEO, said, “We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients. As new GLP‑1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people…” She added, “We delivered a strong finish to the year by executing across our key priorities, expanding manufacturer partnerships, growing differentiated subscription offerings, and strengthening retail relationships.”
Chris McGinnis, Chief Financial Officer, noted, “We closed the year with disciplined financial performance and delivered results in line with our latest guidance. Adjusted EBITDA finished just above the midpoint of our range, reflecting continued cost discipline and focused execution across the business. Pharma Direct grew 41% year‑over‑year, underscoring the strategic progress we are making as we reposition the Company. As we enter 2026, our priority is to operate with rigor, preserve margin strength, and reinforce the long‑term durability of our platform.”
The partnership expands GoodRx’s reach into the high‑growth GLP‑1 market, offering an oral weight‑loss option that can be taken at any time of day. By adding Foundayo and Zepbound KwikPen to its Pharma Direct catalog, GoodRx is positioning itself to capture a larger share of the $42 billion projected GLP‑1 market by 2035, while offsetting declines in its core prescription‑transaction business. The move underscores the company’s strategic pivot toward higher‑margin, manufacturer‑partnered services.
Investors responded positively to the partnership announcement, recognizing the potential for growth in the GLP‑1 segment, but expressed caution regarding the 2026 guidance miss, which signals headwinds in the company’s core marketplace and a need for continued margin preservation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.